Physician profile
Collin S Bowe
NPI 1760896625
$1,008.86
in general payments reported to CMS, 2019-2025
10 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.80 · 2021: $175 · 2022: $194 · 2023: $208 · 2024: $141 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $268.24 | 2019-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $249.15 | 2021-2022 | |
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.39 | 2025 | |
| Pfizer INC. | $89.94 | 2021-2024 | |
| Vertex Pharmaceuticals Incorporated | $43.62 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.50 | 2023-2024 | Xifaxan |
| Global Blood Therapeutics, INC. | $41.08 | 2022 | |
| Haemonetics Corporation | $21.93 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $16.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Bowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.